Compare Adaptive Biotechnologies Corp (ADPT) vs Arm Holdings plc (ARM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Arm Holdings plc — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Arm Holdings plc trades at $296.89 (market cap $320.88B). The key difference: Arm Holdings plc is far larger — about 96.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ADPT | ARM | |
|---|---|---|
Market Cap | $3.33B | $320.88B |
Sector | Health | Technology |
52-Week High | $22.37 | $439.46 |
52-Week Low | $10.24 | $104.55 |
Enterprise Value | $3.19B | $317.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ARM Holdings trades at $322.24, up 2.21% today but showing bearish technical momentum with key support at $317. The stock maintains strong fundamentals with 97.54% gross margins and consistent earnings beats, though valuation ratios remain elevated (P/E 379.11). Recent news highlights AI-driven growth in licensing and data center expansion, despite a 35% pullback from June 2026 peaks.
Outlook is mixed: robust AI demand and analyst optimism (74% buy ratings) support upside potential, but high valuation and technical weakness pose near-term risks. The consensus price target of $321.65 aligns with current levels, suggesting cautious optimism amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →
